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Abstract
Atypical Depression (AD) is a subtype of depression that has a more chronic
course and higher recurrence rate than Major Depressive Disorder (MDD),
leading to the question: For adults over the age of 15 (P), does treatment of
atypical depression with cognitive behavioral therapy (I) provide greater relief
from symptoms (O) than treatment with the standard of care-- selective serotonin
reuptake inhibitors (SSRIs) (C)? A literature search was performed, and five
articles were analyzed. Collectively the studies demonstrated the efficacy of CBT
for the treatment of atypical depression. The studies demonstrated varying
efficacy of SSRI’s. Therefore, more research needs to be done to conclude
whether CBT provides greater symptoms relief than SSRI’s in the treatment of
AD. This study suggests that a multifactorial treatment approach involving both
CBT and SSRI’s is efficacious until further research can be done, and conclusions
made.
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Introduction
Methods
❖ Literature search performed in December 2019 using Academic Search 
Premier, PubMed, and Google Scholar. 
❖ Exclusion Criteria:
1. Neither CBT or SSRI’s were used as a treatment modality. 
2. Another psychiatric condition was primarily being evaluated (i.e. 
panic disorder) 
3. Studies involving children.
4. Studies that did not include a clinical trial nor meta-analysis.
❖ Five articles were selected based on their relevance to the research question, 
study design and quality of research. 
5/5 studies demonstrated that CBT was efficacious in treating AD; 
however, there is not enough evidence to suggest that it is superior to 
SSRIs in adult patients. 
❖Stengths
▪ Evaluation of bias & limitations
▪ Included covariates when necessary
▪ Statistically significant results – p value of 0.05.
❖Limitations
▪ Small sample sizes
▪ Study timelines: <10 weeks in 3/5 studies
▪ No long-term follow-up
❖Future Research
▪ Larger sample sizes
▪ Recruitment techniques: only referred by clinicians
▪ Longer study timelines & long term follow-up
▪ More RCTs 
▪ Study populations that are similar to clinical presentation
Discussion 
Table 1. Comparison of study designs  
Note: *p=.005
Results
Efficacy of Cognitive Behavioral Therapy Compared to Standard of 
Care in the Treatment of Atypical Depression in Adult Patients.
The statistical significance demonstrated in these studies supports treatment of 
atypical depression with CBT as a viable and effective option. However, there 
is not enough evidence to suggest it is superior to other treatments, such as SSRI. 
Overall, the clinical significance of these studies suggests that multiple 
treatment modalities were found to be beneficial for atypically depressed 
patients, which is a success for atypical depression. 
It is plausible that a combination treatment may be most efficacious for these 
patients and should continue to be evaluated in future research. Future research 
should attempt to increase sample size, include long term follow-up and study 
populations that are more similar to clinical presentation.
Conclusion
❖ Significant findings in four of five studies that CBT can 
symptomatically improve individuals with atypical depression.
❖ In the remaining study, SERT densities were shown to improve 
with CBT; however, no quantifiable improvement was 
demonstrated on the HAM-D. 
❖ Henkel et al: changes from baseline depression scales were 
comparable and not significant when comparing CBT to clinical 
management. They demonstrated that there was no significant 
difference in baseline depression scales when treated with SSRIs 
or placebo. 
❖ Cuijpers et al: concluded that effects of CBT and ADM do not 
differ significantly for atypical subtypes of depression.
❖ Parker et al: While CBT does not demonstrate any significant 
differences in treatment effectiveness for atypical and nontypical 
depressed patients, SSRIs, specifically paroxetine and sertraline, 
were significantly less effective in treating atypical groups.
Table 2. Example Table
Atypical Depression
Overview:
❖ Differentiating criteria includes mood reactivity, hyperphagia, hypersomnia, 
interpersonal rejection sensitivity.
❖ More chronic course with higher recurrence, occurring mostly in young women. 
High rate of comorbidity with other psychiatric disorders. 
❖ Unknown etiology, but evidence that it differs from MDD.
Treatment: 
❖ Differential treatment response to monoamine oxidase inhibitors (MAOIs).
❖ Current standard of care: SSRIs 
Relevance: 
❖ With a differing pathophysiology, diagnostic criteria and lack of treatment 
protocols, AD could be treated more effectively with alternative methods than 
pharmacotherapy. 
































48 Sertraline group  
(50-200 mg) 
Placebo group









22 NA 12 months Psychotherapy 
sessions 2x/week 
for 45 min (~80 
total)













Varied Varied (and 
unknown)
“Effectiveness” 4-
point scale: very 







10 NA 16 weeks Weekly IDS-C, BADS, 
SDS
Study Total Effect Size HRSD IDS-C SERT density DAT density Self-reported 
Effectiveness scale
Cuijpers et al. 
(2016)
NS S2 N/A N/A N/A N/A
Henkel et al 
(2010)
NS NS S N/A N/A N/A
Lehto et al 
(2008)
S NS N/A S NS N/A
Parker et al. 
(2009)
S N/A N/A N/A N/A SP
Weinstock et al 
(2011)
S N/A S N/A N/A N/A
Table 2. Comparison of study results  
